North Florida Foundation for Research and Education   Report issue

Foundation Phase 1 Phase 2 Phase 4
Founded: Gainesville FL United States (1997)

Organization Overview

First Clinical Trial
2005
NCT00322699
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

North Florida Foundation for Research and Education

Active Ingredients

Drugs in Phase 4 Trials (1)

testosterone (delatestryl) (2 trials)

Drugs in Phase 2 Trials (2)

porfimer (photofrin) (1 trial)

ranolazine (ranexa) (2 trials)

Drugs in Phase 1 Trials (1)

eplerenone (inspra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angina Pectoris (Phase 2)

Aortic Valve Stenosis (Phase 1)

Central Nervous System Diseases (Phase 2)

Disease (Phase 2)

Endocrine System Diseases (Phase 2)

Gait Disorders, Neurologic (Phase 2)

Gonadal Disorders (Phase 2)

Hypogonadism (Phase 4)

Mobility Limitation (Phase 2)

Nervous System Diseases (Phase 2)

Spinal Cord Diseases (Phase 2)

Spinal Cord Injuries (Phase 2)

Spinal Injuries (Phase 2)

Trauma, Nervous System (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 4